How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about cabozantinib with nivolumab

Marketing authorisation indication

2.1

Cabozantinib (Cabometyx, Ipsen) with nivolumab (Opdivo, Bristol Myers Squibb) is indicated for 'the first-line treatment of advanced renal cell carcinoma in adults'.

Price

2.3

The list price of cabozantinib is £5,143.00 per 30 20-mg, 40-mg or 60-mg tablets (excluding VAT; BNF accessed September 2023). Costs may vary in different settings because of negotiated procurement discounts.

2.4

The list price of nivolumab is £439.00 per 10 mg vial for infusion, £1,317.00 per 120 mg vial for infusion and £2,633.00 per 240 mg vial for infusion (excluding VAT; BNF accessed September 2023). Costs may vary in different settings because of negotiated procurement discounts.

2.5

The companies have commercial arrangements. These make cabozantinib and nivolumab available to the NHS with discounts, which would have also applied to this indication if cabozantinib plus nivolumab had been recommended. The size of the discounts are commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discount.